Gallbladder Volvulus and the Use of Indocyanine Green

Why It Matters

ICG’s ability to instantly delineate biliary structures reduces operative time and the risk of bile duct injury, supporting wider adoption in complex laparoscopic procedures.

Key Takeaways

• ICG provides real‑time biliary mapping during laparoscopy
• Gallbladder volvulus complicates critical view of safety
• ICG outperforms cholangiography in speed and visualization
• Early ICG use may lower bile duct injury rates
• Fluorescence imaging supports safer management of rare biliary emergencies

Pulse Analysis

The recent case report of a 65‑year‑old patient with a necrotic gallbladder volvulus highlights a persistent blind spot in minimally invasive surgery: distorted biliary anatomy that can jeopardize the critical view of safety. By administering indocyanine green (ICG) before incision, surgeons obtained fluorescence‑enhanced visualization of the common bile duct, cystic duct, and even a thrombosed cystic artery. This real‑time mapping allowed the team to detorse the volvulus, confirm tissue viability, and proceed with a standard laparoscopic cholecystectomy despite the atypical presentation.

Compared with traditional intra‑operative cholangiography, ICG offers several operational advantages. The dye is injected intravenously and produces immediate fluorescence, eliminating the need for catheter placement, radiation exposure, and image‑processing delays. In the reported case, ICG expedited identification of the biliary structures, reducing potential operative time and lowering the risk of common bile duct injury—a complication that can add millions of dollars in downstream costs. Early studies suggest that routine ICG use can cut average procedure duration by 10‑15 minutes and improve safety metrics across complex gallbladder surgeries.

The successful application of ICG in a rare gallbladder volvulus scenario signals a broader market opportunity for fluorescence imaging platforms. Hospital systems seeking to enhance surgical outcomes are increasingly allocating capital toward near‑infrared cameras and disposable ICG kits, which now cost roughly $30‑$50 per dose. As payer policies begin to recognize the cost‑avoidance potential of fewer bile duct injuries, reimbursement models are expected to favor technologies that demonstrably reduce complications. Consequently, device manufacturers and surgical innovators are likely to accelerate R&D, positioning ICG‑guided laparoscopy as a new standard for high‑risk biliary procedures.